Global market access consulting
Global market access capabilities
Our global biopharma consulting capabilities
Health economics & outcomes research
Market access consulting
When launching products outside the U.S., Xcenda provides deep understanding of the environment, competition, and considerations for market access across Europe and HTA countries. We evaluate how your product many be viewed by payers and assess what may be needed beyond your clinical trials.
With strategic global data partnerships in the US, Germany, the UK, the Netherlands, France, Sweden, Canada, Japan, and China, we support our clients' global strategies along the entire product lifecycle.
Our databases are sourced from administrative claims, electronic medical records, or disease registries, and capture patient-level health information and outcomes for healthcare services performed in various care settings.
Ask local experts from markets worldwide
Global market access network
Our global market access and consulting insights
Market access abroad: Three reasons why early planning is critical for HTA countries
Regulatory approval may represent a giant leap forward in a product's path to commercialization, but in Europe and several other regions, it is far from the last step. In these markets, health technology assessments (HTAs) add complexity and nuance to global launch plans. HTAs mandate formal documentation, robust evidentiary requirements, and other activities that convey a therapy's value. If every obligation is not met, it can delay market entry.
Avoid product launch delays with a well-prepared market access strategy
The new EU regulation on health technology assessment: Major change or minor adjustment?
Orphan drugs: trapped in the lock? A review of the lock system in the Netherlands
Whilst orphan diseases individually are rare, collectively they are not; population prevalence of rare diseases is put at 5% to 10%. Whilst developers look for high prices to cover their costs, can payers afford them? A review of the “lock” system in the Netherlands suggests maybe not.